First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Pat

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies
The...

Related Keywords

Hamburg , Germany , United States , Eppendorf , Nordrhein Westfalen , Peter Maag , Christoph Heesen , Department Of Stem Cell Transplantation , National Institutes Of Health , University Medical Center Hamburg , Kyverna Therapeutics Inc , Kyverna Therapeutics , University Medical Center Hamburg Eppendorf , Stem Cell Transplantation , Northern European , National Institutes , Media Contact , Nature Medicine , Markets ,